Header Logo

Connection

Annette Langer-Gould to Humans

Back to Details
This is a "connection" page, showing publications Annette Langer-Gould has written about Humans.
Annette Langer-Gould
Connection Strength
3.052
Humans
  1. Anti-NMDA receptor encephalitis outcomes in a population-based cohort. J Neurol. 2026 Jul 15; 273(8).
    View in: PubMed
    Score: 0.071
  2. De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
    View in: PubMed
    Score: 0.069
  3. Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
    View in: PubMed
    Score: 0.068
  4. Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level. Neurology. 2025 May 27; 104(10):e213607.
    View in: PubMed
    Score: 0.065
  5. Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility. Mult Scler. 2025 Apr; 31(5):539-547.
    View in: PubMed
    Score: 0.064
  6. Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: No. Mult Scler. 2024 Dec; 30(5_suppl):9-11.
    View in: PubMed
    Score: 0.063
  7. Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200255.
    View in: PubMed
    Score: 0.061
  8. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
    View in: PubMed
    Score: 0.060
  9. Disparities in Maternal and Infant Outcomes: What's a Neurologist to Do? Neurology. 2024 02 27; 102(4):e209207.
    View in: PubMed
    Score: 0.060
  10. Rituximab for Multiple Sclerosis: Hiding in Plain Sight Neurology. 2024 01 23; 102(2):e208063.
    View in: PubMed
    Score: 0.059
  11. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
    View in: PubMed
    Score: 0.059
  12. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4).
    View in: PubMed
    Score: 0.057
  13. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Netw Open. 2022 12 01; 5(12):e2248664.
    View in: PubMed
    Score: 0.055
  14. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness. Int J Infect Dis. 2023 Jan; 126:87-93.
    View in: PubMed
    Score: 0.055
  15. High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness. Int J Infect Dis. 2022 Dec; 125:184-191.
    View in: PubMed
    Score: 0.055
  16. The Role of Diet in Multiple Sclerosis: Food for Thought. Neurology. 2023 Jan 24; 100(4):167-168.
    View in: PubMed
    Score: 0.055
  17. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022 05 03; 98(18):e1818-e1827.
    View in: PubMed
    Score: 0.053
  18. Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US: A Review. JAMA Neurol. 2021 12 01; 78(12):1515-1524.
    View in: PubMed
    Score: 0.051
  19. Open Access Fees: A Barrier to Scholarly Activity Among Neurology Trainees. Perm J. 2021 Nov 29; 25.
    View in: PubMed
    Score: 0.051
  20. Reader Response: Leadership, Recognition Awards, and Publication by Men and Women in the American Academy of Neurology. Neurology. 2021 07 27; 97(4):200-201.
    View in: PubMed
    Score: 0.050
  21. Treating severe MS relapses during pregnancy. Mult Scler. 2021 09; 27(10):1623-1624.
    View in: PubMed
    Score: 0.049
  22. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
    View in: PubMed
    Score: 0.049
  23. Improving quality, affordability, and equity of multiple sclerosis care. Ann Clin Transl Neurol. 2021 04; 8(4):980-991.
    View in: PubMed
    Score: 0.049
  24. Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
    View in: PubMed
    Score: 0.049
  25. An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis. Mult Scler. 2021 09; 27(10):1611-1614.
    View in: PubMed
    Score: 0.048
  26. Editorial Response to Drs. Simone and Mancusi. Int J Infect Dis. 2020 12; 101:367.
    View in: PubMed
    Score: 0.047
  27. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis. 2020 Oct; 99:291-297.
    View in: PubMed
    Score: 0.047
  28. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.046
  29. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020 05 05; 94(18):e1939-e1949.
    View in: PubMed
    Score: 0.046
  30. Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology. 2020 04 07; 94(14):e1548-e1556.
    View in: PubMed
    Score: 0.046
  31. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019 09; 6(9):1905-1922.
    View in: PubMed
    Score: 0.044
  32. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019 Jun; 25(3):773-792.
    View in: PubMed
    Score: 0.043
  33. Vitamin D deficiency is an etiological factor for MS - No. Mult Scler. 2019 04; 25(5):639-641.
    View in: PubMed
    Score: 0.042
  34. MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. Nutrients. 2018 Feb 27; 10(3).
    View in: PubMed
    Score: 0.040
  35. Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis. Nutrients. 2018 Feb 07; 10(2).
    View in: PubMed
    Score: 0.039
  36. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study. Neurology. 2017 Sep 26; 89(13):1330-1337.
    View in: PubMed
    Score: 0.038
  37. Breastfeeding, ovulatory years, and risk of multiple sclerosis. Neurology. 2017 Aug 08; 89(6):563-569.
    View in: PubMed
    Score: 0.038
  38. Breastfeeding and Disease-Modifying Therapy for Multiple Sclerosis--Reply. JAMA Neurol. 2016 Apr; 73(4):480-1.
    View in: PubMed
    Score: 0.035
  39. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. PLoS One. 2016; 11(3):e0149094.
    View in: PubMed
    Score: 0.035
  40. Sex hormones and multiple sclerosis: another informative failure. Lancet Neurol. 2016 Jan; 15(1):22-3.
    View in: PubMed
    Score: 0.034
  41. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol. 2015 Oct; 72(10):1132-8.
    View in: PubMed
    Score: 0.034
  42. Association between vaccines and neuroinflammation-reply. JAMA Neurol. 2015 May; 72(5):605.
    View in: PubMed
    Score: 0.033
  43. Place of birth,age of immigration,and disability in Hispanics with multiple sclerosis. Mult Scler Relat Disord. 2015 Jan; 4(1):25-30.
    View in: PubMed
    Score: 0.032
  44. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014 Dec; 71(12):1506-13.
    View in: PubMed
    Score: 0.032
  45. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014 Oct 28; 83(18):1685.
    View in: PubMed
    Score: 0.031
  46. The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol. 2014 Jul; 261(7):1349-55.
    View in: PubMed
    Score: 0.030
  47. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014 Feb 25; 82(8):654-5.
    View in: PubMed
    Score: 0.030
  48. Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J. 2014; 18(1):9-13.
    View in: PubMed
    Score: 0.030
  49. One can prevent post-partum MS relapses by exclusive breast feeding: yes. Mult Scler. 2013 Oct; 19(12):1567-8.
    View in: PubMed
    Score: 0.029
  50. Spinal cord lesions and disability in Hispanics with multiple sclerosis. J Neurol. 2013 Nov; 260(11):2770-6.
    View in: PubMed
    Score: 0.029
  51. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013 May 07; 80(19):1734-9.
    View in: PubMed
    Score: 0.028
  52. Reply: To PMID 22633290. J Pediatr. 2013 May; 162(5):1084.
    View in: PubMed
    Score: 0.028
  53. The American Academy of Neurology's top five choosing wisely recommendations. Neurology. 2013 Sep 10; 81(11):1004-11.
    View in: PubMed
    Score: 0.028
  54. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013 Feb 05; 80(6):548-52.
    View in: PubMed
    Score: 0.028
  55. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol. 2013 Nov; 149(2):244-50.
    View in: PubMed
    Score: 0.028
  56. Pediatric idiopathic intracranial hypertension and extreme childhood obesity. J Pediatr. 2012 Oct; 161(4):602-7.
    View in: PubMed
    Score: 0.027
  57. Vitamin D levels in Hispanics with multiple sclerosis. J Neurol. 2012 Dec; 259(12):2565-70.
    View in: PubMed
    Score: 0.027
  58. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011 Sep 20; 77(12):1143-8.
    View in: PubMed
    Score: 0.025
  59. Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses. Arch Neurol. 2011 Mar; 68(3):310-3.
    View in: PubMed
    Score: 0.024
  60. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010 Jul; 16(7):855-61.
    View in: PubMed
    Score: 0.023
  61. Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis. Arch Neurol. 2010 Jan; 67(1):51-7.
    View in: PubMed
    Score: 0.023
  62. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009 Aug; 66(8):958-63.
    View in: PubMed
    Score: 0.022
  63. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
    View in: PubMed
    Score: 0.022
  64. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec; 63(12):1686-91.
    View in: PubMed
    Score: 0.018
  65. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep. 2006 May; 6(3):253-8.
    View in: PubMed
    Score: 0.017
  66. What went wrong in the natalizumab trials? Lancet. 2006 Mar 04; 367(9512):708-10.
    View in: PubMed
    Score: 0.017
  67. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4):375-81.
    View in: PubMed
    Score: 0.016
  68. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S35-41.
    View in: PubMed
    Score: 0.016
  69. Stakeholder-informed pragmatic trial protocol of the TabCAT-BHA for the detection of cognitive impairment in primary care. BMC Prim Care. 2024 Aug 06; 25(1):286.
    View in: PubMed
    Score: 0.015
  70. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023 07 01; 80(7):693-701.
    View in: PubMed
    Score: 0.014
  71. The impact of timing of initiating invasive mechanical ventilation in COVID-19-related respiratory failure. J Crit Care. 2023 10; 77:154322.
    View in: PubMed
    Score: 0.014
  72. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult Scler. 2023 05; 29(6):731-740.
    View in: PubMed
    Score: 0.014
  73. The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study. J Hosp Med. 2023 01; 18(1):43-54.
    View in: PubMed
    Score: 0.014
  74. COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol. 2022 09; 9(9):1449-1458.
    View in: PubMed
    Score: 0.014
  75. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
    View in: PubMed
    Score: 0.013
  76. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
    View in: PubMed
    Score: 0.012
  77. Safety of potential breast milk exposure to IFN-ß or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.012
  78. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
    View in: PubMed
    Score: 0.012
  79. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
    View in: PubMed
    Score: 0.011
  80. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
    View in: PubMed
    Score: 0.011
  81. Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology. 2019 03; 30(2):230-233.
    View in: PubMed
    Score: 0.011
  82. A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS. Neurology. 2019 03 05; 92(10):469-480.
    View in: PubMed
    Score: 0.011
  83. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019 03 05; 92(10):e1029-e1040.
    View in: PubMed
    Score: 0.011
  84. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
    View in: PubMed
    Score: 0.011
  85. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808.
    View in: PubMed
    Score: 0.011
  86. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016 05; 22(6):801-9.
    View in: PubMed
    Score: 0.009
  87. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016 05; 22(6):810-6.
    View in: PubMed
    Score: 0.009
  88. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014 Jul 01; 71(7):891-5.
    View in: PubMed
    Score: 0.008
  89. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014 Jun; 34(6):435-40.
    View in: PubMed
    Score: 0.008
  90. The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10; 81(11):1022-3.
    View in: PubMed
    Score: 0.007
  91. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012; 16(3):37-41.
    View in: PubMed
    Score: 0.006
  92. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler. 2012 Mar; 18(3):377-8.
    View in: PubMed
    Score: 0.006
  93. Health plan administrative records versus birth certificate records: quality of race and ethnicity information in children. BMC Health Serv Res. 2010 Nov 23; 10:316.
    View in: PubMed
    Score: 0.006
  94. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
    View in: PubMed
    Score: 0.005
  95. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003 Nov-Dec; 24(10):1941-5.
    View in: PubMed
    Score: 0.004
  96. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002 May; 8(5):500-8.
    View in: PubMed
    Score: 0.003

© 2026 Kaiser Permanente

Your Privacy Choices